- Home
- CKPT
as 01-21-2025 4:00pm EST
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 151.9M | IPO Year: | 2017 |
| Target Price: | $13.50 | AVG Volume (30 days): | 998.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.38 - $4.50 | Next Earning Date: | 11-12-2024 |
| Revenue: | $47,000 | Revenue Growth: | -72.51% |
| Revenue Growth (this year): | -76.23% | Revenue Growth (next year): | 172016.02% |
Stock Insider Trading Activity of Checkpoint Therapeutics Inc. (CKPT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GRAY WILLIAM GARRETT | CKPT | Chief Financial Officer | Dec 18 '24 | Sell | $4.01 | 268,432 | $1,076,412.32 | 1,032,754 | |
| Oliviero James F III | CKPT | CEO, President and Director | Dec 18 '24 | Sell | $3.63 | 822,397 | $3,074,763.69 | 3,414,813 |
Latest Checkpoint Therapeutics Inc. News
CKPT Breaking Stock News: Dive into CKPT Ticker-Specific Updates for Smart Investing
Argus Research
a month ago
Daily – Vickers Top Buyers & Sellers for 12/23/2024
MT Newswires
a month ago
Checkpoint Therapeutics Insider Sold Shares Worth $1,076,412, According to a Recent SEC Filing
MT Newswires
a month ago
Checkpoint Therapeutics Insider Sold Shares Worth $3,074,764, According to a Recent SEC Filing
Benzinga
a month ago
FDA Approves Checkpoint Therapeutics' Skin Cancer Drug One Year After Rejection
BioPharma Dive
a month ago
Novo builds up manufacturing; Pepgen Duchenne trial put on hold
GlobeNewswire
a month ago
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
Simply Wall St.
2 months ago
Checkpoint Therapeutics Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.29 loss in 3Q 2023)
GlobeNewswire
2 months ago
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Compare CKPT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CKPT Checkpoint Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.